NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 1 June 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Alex Cale Present for all items
4. Dr Prithwiraj Das Present for all items
5. Dr David Foreman Present for all items
6. Dr Rob Forsyth Present for all items
7. Dr Natalie Hallas Present for all items
8. John Hampson Present for all items
9. Dr Nigel Langford Present for all items
10. Iain McGowan Present for all items
11. Kirandip Moyo Items 1 to 4.1.3 & 5.1.3 to 5.2.2
12. Dr Mudasar Mushtaq Items 1 to 4.2.2
13. Ugochi Nwulu Present for all items
14. Stella O’Brien Present for all items
15. Professor Subhash Pokhrel Present for all items
16. Professor Andrew Renehan Items 1 to 4.1.3
17. Professor Matthew Stevenson Items 1 to 4.2.2 and 5.1.3 to 5.2.2
18. Professor Paul Tappenden Present for all items
19. Dr Derek Ward Present for all items

NICE staff present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager Present for all items

Charlie Hewitt, Heath Technology Assessment Adviser Items 1 to 4.2.2

Louise Crathorne, Heath Technology Assessment Adviser Items 1 to 4.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 5 to 5.2.2

Anuja Chatterjee, Health Technology Assessment Analyst Present for all items

Owen Swales, Heath Technology Assessment Analyst Items 1 to 4.2.2

Anita Sanga, Heath Technology Assessment Analyst Items 5 to 5.2.2

Anna Willis, Heath Technology Assessment Analyst Items 5 to 5.2.2

Benjamin Gregory, Business Analyst, RIA Present for all items

Ella Livingstone, Technical Analyst, Commercial Risk Assessment Present for all items

Stephen Norton, Health Technology Assessment Analyst, Managed Access, Items 1 to 4.2.2

Emilene Coventry, Senior Medical Editor Items 1 to 4.2.2

Anna Sparshatt, Senior Medical Editor Items 5 to 5.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 5 to 5.2.2

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Present for all items

External assessment group representatives present

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3 & 5 to 5.1.3

Isaac Corro Ramos, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Willem Witlox, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all items

Dr Kate Cwynarski, Consultant Haematologist, Clinical expert nominated by Incyte & NCRI-ACP-RCP-RCR, Items 1 to 4.1.3

Professor Andrew Davies, Consultant Medical Oncology, Clinical expert nominated by Incyte, Items 1 to 4.1.3

Professor Charles Craddock, Professor of Haemato-oncology, Clinical expert nominated by Celgene, Items 5 to 5.1.3

Dr Manoj Raghavan, Clinical Senior Lecturer and Honorary Consultant Haematologist, Clinical expert nominated by RCP, Items 5 to 5.1.3

Martin Burr, Patient expert nominated by Leukaemia Care, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. This will be the final meeting for Committee members: Dr Mudasar Mushtaq and Kirandip Moyo.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 4 May 2022.

### Appraisal of tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Incyte Corporation
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared direct financial interests as he has attended paid advisory boards with Novartis and Roche (named comparator companies) in an unrelated disease area (MS). It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
* Nominated clinical expert Dr Kate Cwynarski declared direct financial and indirect interests as she has received consulting/advisory fees from, Roche, Takeda, Celgene, Atara, Gilead, KITE, Janssen and Incyte, speaker fees from Roche, Takeda, KITE, Gilead and Incyte, conference/travel support from Roche, Takeda, KITE, Janssen and BMS. it was agreed that her declarations would not prevent Dr Cwynarski from providing expert advice to the committee.
* Nominated clinical expert Professor Andrew Davies declared direct financial interests as he has received payment to attend an Incyte hosted clinical advisory board meeting and has reviewed health economic data that in part contributes to this submission, for which he was renumerated and he has received honoraria, advisory and speaker fees from Roche (named comparator company). It was agreed that his declarations would not prevent Professor Davies from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by John Hampson, Ugochi Nwulu, and Dr Natalie Hallas.
	1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10645>.

### Appraisal of oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Celgene, a BMS company.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared direct financial interests as he has attended paid advisory boards with Novartis (named comparator company) in an unrelated disease area (MS). It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
* Nominated patient expert Martin Burr declared indirect financial interests as in the last 12 months Leukaemia Care has received funding from Novartis and Pfizer. It was agreed his declaration would not prevent Mr Burr from providing expert advice to the committee.
* Nominated clinical expert Professor Charles Craddock declared direct financial interests as he has received consultancy, speaker, and advisory fees from Abbvie, Astellas, BMS, Celgene, Daiichi Sankyo, Eurocept, Janssen, Novartis and Pfizer, research support and consultancy fees from Jazz & KITE and consultancy and speaker fees from Roche. It was agreed his declaration would not prevent Professor Craddock from providing expert advice to the committee.
* Nominated clinical expert Dr Manoj Raghavan declared direct financial and non-financial interests as in 2021 he received advisory fees from Jazz Pharmaceuticals and Pfizer UK, he has held speaker contracts with Astellas Pharmaceuticals and Incyte Biosciences, and he is also a member of the MDS subgroup of NCRI Haemato-oncology CSSG and the UK MDS Forum. It was agreed his declaration would not prevent Dr Raghavan from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Derek Ward, Ugochi Nwulu, and Dr Prithwiraj Das.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10775>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 5 July 2022 and will start promptly at 09.30.